Comparative Pharmacology
Head-to-head clinical analysis: TRITEC versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRITEC versus ZANTAC.
TRITEC vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist/Antimicrobial Combination
H2 Receptor Antagonist